Skip Navigation
Researcher
Rivkin awardees publish at the top of the field

Of publications authored by past Rivkin grant award recipients, 55% have been published in the top journals for scientific research. Here are a few recent publications by Rivkin-funded researchers.

  • 2011

    Benitez AC, Dai Z, Mann HH, Reeves RS, Margineantu DH, Gooley TA, Groh V, Spies T. Expression, signaling proficiency, and stimulatory function of the NKG2D lymphocyte receptor in human cancer cells. Proc Natl Acad Sci U S A. 2011 Mar 8;108(10):4081-6.

    Boldt HB, Conover CA. Overexpression of pregnancy-associated plasma protein-A in ovarian cancer cells promotes tumor growth in vivo. Endocrinology. 2011 Apr;152(4):1470-8.

    Fotheringham S, Levanon K, Drapkin R. Ex vivo culture of primary human fallopian tube epithelial cells. Journal of visualized experiments : JoVE. 2011(51).

    Karst AM, Levanon K, Drapkin R. Modeling high-grade serous ovarian carcinogenesis from the fallopian tube. Proc Natl Acad Sci U S A. 2011 May 3;108(18):7547-52.

    Norquist B, Wurz KA, Pennil CC, Garcia R, Gross J, Sakai W, Karlan BY, Taniguchi T, Swisher EM. Secondary Somatic Mutations Restoring BRCA1/2 Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas. J Clin Oncol. 2011 Aug 1;29(22):3008-15.

    Righi E, Kashiwagi S, Yuan J, Santosuosso M, Leblanc P, Ingraham R, Forbes B, Edelblute B, Collette B, Xing D, Kowalski M, Mingari MC, Vianello F, Birrer M, Orsulic S, Dranoff G, Poznansky MC. CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer. Cancer Res. 2011 Aug 15;71(16):5522-34.

    Sand-Dejmek J, Adelmant G, Sobhian B, Calkins AS, Marto J, Iglehart DJ, Lazaro JB. Concordant and opposite roles of DNA-PK and the "facilitator of chromatin transcription" (FACT) in DNA repair, apoptosis and necrosis after cisplatin. Mol Cancer. 2011;10:74.

    Theriault BL, Nachtigal MW. Human ovarian cancer cell morphology, motility, and proliferation are differentially influenced by autocrine TGFbeta superfamily signalling. Cancer Lett. 2011 Dec 26;313(1):108-21.

    Thrall MM, Gray HJ, Symons RG, Weiss NS, Flum DR, Goff BA. Neoadjuvant chemotherapy in the Medicare cohort with advanced ovarian cancer. Gynecol Oncol. 2011 Sep 24. [Epub ahead of print].

    Thrall MM, Gray HJ, Symons RG, Weiss NS, Flum DR, Goff BA. Trends in treatment of advanced epithelial ovarian cancer in the Medicare population. Gynecol Oncol. 2011 Jul;122(1):100-6.

    Wang E, Bhattacharyya S, Szabolcs A, Rodriguez-Aguayo C, Jennings NB, Lopez-Berestein G, Mukherjee P, Sood AK, Bhattacharya R. Enhancing chemotherapy response with Bmi-1 silencing in ovarian cancer. PLoS ONE. 2011;6(3):e17918.

    Wilken JA, Baron AT, Foty RA, McCormick DJ, Maihle NJ. Identification of immunoreactive regions of homology between soluble epidermal growth factor receptor and alpha5-integrin. Biochemistry. 2011 May 24;50(20):4309-21.

  • 2010

    Andersen M, Goff B, Lowe K, Scholler N, Bergan L, Drescher C, Paley P, Urban N. Use of a Symptom Index, CA125 and HE4 to predict ovarian cancer. Gynecol Oncol. 2010 Mar;116(3):378-83.

    Annunziata CM, Stavnes HT, Kleinberg L, Berner A, Hernandez LF, Birrer MJ, Steinberg SM, Davidson B, Kohn EC. Nuclear factor kappaB transcription factors are coexpressed and convey a poor outcome in ovarian cancer. Cancer. 2010 Jul 1;116(13):3276-84.

    Hernandez L, Hsu SC, Davidson B, Birrer MJ, Kohn EC, Annunziata CM. Activation of NF-kappaB signaling by inhibitor of NF-kappaB kinase beta increases aggressiveness of ovarian cancer. Cancer Res. 2010 May 15;70(10):4005-14.

    King ER, Tung CS, Tsang YT, Zu Z, Lok GT, Deavers MT, Malpica A, Wolf JK, Lu KH, Birrer MJ, Mok SC, Gershenson DM, Wong KK. The anterior gradient homolog 3 (AGR3) gene is associated with differentiation and survival in ovarian cancer. Am J Surg Pathol. 2011 Jun;35(6):904-12.

    Wilken JA, Webster KT, Maihle, NJ. Trastuzumab sensitizes ovarian cancer cells to EGFR-targeted therapeutics. J Ovarian Res. 2010; 3(7):1-9. Open access.

    Wong KK, Tsang YT, Deavers MT, Mok SC, Zu Z, Sun C, Malpica A, Wolf JK, Lu KH, Gershenson DM. BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas. Am J Pathol. 2010 Oct;177(4):1611-7.

  • 2009

    Anderson NS, Bermudez Y, Badgwell D, Chen R, Nicosia SV, Bast RC Jr, Kruk PA. Urinary levels of Bcl-2 are elevated in ovarian cancer patients. Gynecol Oncol. 2009 Jan;112(1):60-7.

    Baron AT, Wilken JA, Haggstrom DE, Goodrich ST, Maihle NJ. Clinical implementation of soluble EGFR (sEGFR) as a theragnostic serum biomarker of breast, lung and ovarian cancer. IDrugs. 2009 May;12(5):302-8. Review.

    Berchuck A, Iversen ES, Luo J, Clarke JP, Horne H, Levine DA, Boyd J, Alonso MA, Secord AA, Bernardini MQ, Barnett JC, Boren T, Murphy SK, Dressman HK, Marks JR, Lancaster JM. Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome. Clin Cancer Res. 2009 Apr 1;15(7):2448-55.

    Clarke B, Tinker AV, Lee CH, Subramanian S, van de Rijn M, Turbin D, Kalloger S, Han G, Ceballos K, Cadungog MG, Huntsman DG, Coukos G, Gilks CB. Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Mod Pathol. 2009. 22(3):393-402.

    Dejmek J, Iglehart JD, Lazaro JB. DNA-dependent protein kinase (DNA-PK)-dependent cisplatin-induced loss of nucleolar facilitator of chromatin transcription (FACT) and regulation of cisplatin sensitivity by DNA-PK and FACT. Mol Cancer Res. 2009. 7(4):581-91.

    Duan Z, Ames RY, Ryan M, Hornicek FJ, Mankin H, Seiden MV. CDDO-Me, a synthetic triterpenoid, inhibits expression of IL-6 and Stat3 phosphorylation in multi-drug resistant ovarian cancer cells. Cancer Chemother Pharmacol. 2009. 63(4):681-9.

    Duan Z, Choy E, Jimeno JM, Cuevas Cdel M, Mankin HJ, Hornicek FJ. Diverse cross-resistance phenotype to ET-743 and PM00104 in multi-drug resistant cell lines. Cancer Chemother Pharmacol. 2009. 63(6):1121-9.

    Durrant D, Corwin F, Simoni D, Zhao M, Rudek MA, Salloum FN, Kukreja RC, Fatouros PP, Lee RM. cis-3, 4′, 5-Trimethoxy-3′-aminostilbene disrupts tumor vascular perfusion without damaging normal organ perfusion. Cancer Chemother Pharmacol. 2009 63(2):191-200.

    Guo JP, Shu SK, He L, Lee YC, Kruk PA, Grenman S, Nicosia SV, Mor G, Schell MJ, Coppola D, Cheng JQ. Deregulation of IKBKE is associated with tumor progression, poor prognosis, and cisplatin resistance in ovarian cancer. Am J Pathol. 2009 Jul;175(1):324-33

    Johnatty SE, Beesley J, Chen X, Spurdle AB, Defazio A, Webb PM; Australian Ovarian Cancer Study Group; Australian Cancer Study (Ovarian Cancer), Goode EL, Rider DN, Vierkant RA, Anderson S, Wu AH, Pike M, Van Den Berg D, Moysich K, Ness R, Doherty J, Rossing MA, Pearce CL, Chenevix-Trench G. Polymorphisms in the FGF2 gene and risk of serous ovarian cancer: results from the ovarian cancer association consortium. Twin Res Hum Genet. 2009 ;12(3):269-75.

    Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, Wei S, Huang E, Finlayson E, Simeone D, Welling TH, Chang A, Coukos G, Liu R, Zou W. Phenotype, distribution, generation, functional and clinical relevance of Th17 cells in the human tumor environments. Blood. 2009 May 21. [Epub ahead of print]

    Kryczek I, Liu R, Wang G, Wu K, Shu X, Szeliga W, Vatan L, Finlayson E, Huang E, Simeone D, Redman B, Welling TH, Chang A, Zou W. FOXP3 defines regulatory T cells in human tumor and autoimmune disease. Cancer Res. 2009 May 1;69(9):3995-4000.

    Kwong J, Chan FL, Wong KK, Birrer MJ, Archibald KM, Balkwill FR, Berkowitz RS, Mok SC. Inflammatory cytokine tumor necrosis factor alpha confers precancerous phenotype in an organoid model of normal human ovarian surface epithelial cells. Neoplasia. 2009 Jun;11(6):529-41.

    Martin LP, Schilder RJ. Management of recurrent ovarian carcinoma: current status and future directions. Semin Oncol. 2009 Apr;36(2):112-25

    Melnikov A, Scholtens D, Godwin A, Levenson V. Differential methylation profile of ovarian cancer in tissues and plasma. J Mol Diagn. 2009 Jan;11(1):60-5.

    Murph MM, Liu W, Yu S, Lu Y, Hall H, Hennessy BT, Lahad J, Schaner M, Helland A, Kristensen G, Børresen-Dale AL, Mills GB. Lysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian carcinoma and worsened prognosis. PLoS One. 2009;4(5):e5583.

    Pan S, Cheng L, White JT, Lu W, Utleg AG, Yan X, Urban ND, Drescher CW, Hood L, Lin B. Quantitative Proteomics Analysis Integrated with Microarray Data Reveals That Extracellular Matrix Proteins, Catenins, and P53 Binding Protein 1 Are Important for Chemotherapy Response in Ovarian Cancers. OMICS. 2009 May 7. [Epub ahead of print]

    Quaye L, Song H, Ramus SJ, Gentry-Maharaj A, Høgdall E, DiCioccio RA, McGuire V, Wu AH, Van Den Berg DJ, Pike MC, Wozniak E, Doherty JA, Rossing MA, Ness RB, Moysich KB, Høgdall C, Blaakaer J; Ovarian Cancer Association Consortium, Easton DF, Ponder BA, Jacobs IJ, Menon U, Whittemore AS, Krüger-Kjaer S, Pearce CL, Pharoah PD, Gayther SA. Tagging single-nucleotide polymorphisms in candidate oncogenes and susceptibility to ovarian cancer. Br J Cancer. 2009 ;100(6):993-1001.

    Satpathy M, Shao M, Emerson R, Donner DB, Matei D. Tissue transglutaminase regulates MMP-2 in ovarian cancer by modulating CREB activity. J Biol Chem. 2009;284(23):15390-9.

    Schilder RJ, Pathak HB, Lokshin AE, Holloway RW, Alvarez RD, Aghajanian C, Min H, Devarajan K, Ross E, Drescher CW, Godwin AK. Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. Gynecol Oncol. 2009 Apr;113(1):21-7

    Shah CA, Lowe KA, Paley P, Wallace E, Anderson GL, McIntosh MW, Andersen MR, Scholler N, Bergan LA, Thorpe JD, Urban N, Drescher CW. Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125. Cancer Epidemiol Biomarkers Prev. 2009 May;18(5):1365-72.

    Shah SP, Köbel M, Senz J, Morin RD, Clarke BA, Wiegand KC, Leung G, Zayed A, Mehl E, Kalloger SE, Sun M, Giuliany R, Yorida E, Jones S, Varhol R, Swenerton KD, Miller D, Clement PB, Crane C, Madore J, Provencher D, Leung P, DeFazio A, Khattra J, Turashvili G, Zhao Y, Zeng T, Glover JN, Vanderhyden B, Zhao C, Parkinson CA, Jimenez-Linan M, Bowtell DD, Mes-Masson AM, Brenton JD, Aparicio SA, Boyd N, Hirst M, Gilks CB, Marra M, Huntsman DG. Mutation of FOXL2 in granulosa-cell tumors of the ovary. N Engl J Med. 2009 Jun 25;360(26):2719-29.

    Slack-Davis JK, Atkins KA, Harrer C, Hershey ED, Conaway M. Vascular cell adhesion molecule-1 is a regulator of ovarian cancer peritoneal metastasis. Cancer Res. 2009 Feb 15;69(4):1469-76. Epub 2009 Feb 10. Erratum in: Cancer Res. 2009 Mar 15;69(6):2694.

    Song H, Ramus SJ, Kjaer SK, DiCioccio RA, Chenevix-Trench G, Pearce CL, Hogdall E, Whittemore AS, McGuire V, Hogdall C, Blaakaer J, Wu AH, Van Den Berg DJ, Stram DO, Menon U, Gentry-Maharaj A, Jacobs IJ, Webb PM, Beesley J, Chen X; Australian Cancer (Ovarian) Study; Australian Ovarian Cancer Study Group, Rossing MA, Doherty JA, Chang-Claude J, Wang-Gohrke S, Goodman MT, Lurie G, Thompson PJ, Carney ME, Ness RB, Moysich K, Goode EL, Vierkant RA, Cunningham JM, Anderson S, Schildkraut JM, Berchuck A, Iversen ES, Moorman PG, Garcia-Closas M, Chanock S, Lissowska J, Brinton L, Anton-Culver H, Ziogas A, Brewster WR, Ponder BA, Easton DF, Gayther SA, Pharoah PD; Ovarian Cancer Association Consortium (OCAC). Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study. Hum Mol Genet. 2009 Jun;18(12):2297-304

    Strauss R, Sova P, Liu Y, Li ZY, Tuve S, Pritchard D, Brinkkoetter P, Möller T, Wildner O, Pesonen S, Hemminki A, Urban N, Drescher C, Lieber A. Epithelial phenotype confers resistance of ovarian cancer cells to oncolytic adenoviruses. Cancer Res. 2009 Jun 15;69(12):5115-25

    Shuyu E, Lai Y-J, Tsukahara R, Chen C-S, Fujiwara Y, Yue J, Yu J-H, Guo H, Kihara A, Tigyi G and Lin F-T.The LPA2 Receptor-Mediated Supramolecular Complex Formation Regulates Its Antiapoptotic Effect. J. Biol. Chem. 2009; 284:14558-71.

    Tung CS, Mok SC, Tsang YT, Zu Z, Song H, Liu J, Deavers MT, Malpica A, Wolf JK, Lu KH, Gershenson DM, Wong KK. PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas. Mod Pathol. 2009 Jun 12. [Epub ahead of print]

    Williams SJ, Cvetkovic D, Hamilton TC. Vitamin A metabolism is impaired in human ovarian cancer. Gynecol Oncol. 2009 Mar;112(3):637-45.

    Wyman SK, Parkin RK, Mitchell PS, Fritz BR, O’Briant K, Godwin AK, Urban N, Drescher CW, Knudsen BS, Tewari M. Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries. PLoS One. 2009;4(4):e5311

    Zhang Y, Zhang M, Dong H, Yong S, Li X, Olashaw N, Kruk PA, Cheng JQ, Bai W, Chen J, Nicosia SV, Zhang X. Deacetylation of cortactin by SIRT1 promotes cell migration. Oncogene. 2009 Jan 22;28(3):445-60

  • 2008

    Andersen MR, Goff BA, Lowe KA, Scholler N, Bergan L, Dresher CW, Paley P, Urban N. Combining a symptoms index with CA 125 to improve detection of ovarian cancer. Cancer. 2008. 113(3):484-9.

    Bermudez Y, Yang H, Cheng JQ, Kruk PA. Pyk2/ERK 1/2 mediate Sp1- and c-Myc-dependent induction of telomerase activity by epidermal growth factor. Growth Factors. 2008 Feb;26(1):1-11.

    Brown LA, Kalloger SE, Miller MA, Shih IeM, McKinney SE, Santos JL, Swenerton K, Spellman PT, Gray J, Gilks CB, Huntsman DG. Amplification of 11q13 in ovarian carcinoma. Genes Chromosomes Cancer. 2008. 47(6):481-9.

    Cao L, Petrusca DN, Satpathy M, Nakshatri H, Petrache I, Matei D. Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling. Carcinogenesis. 2008. 29(10):1893-900.

    Corney DC, Flesken-Nikitin A, Choi J, Nikitin AY. Role of p53 and Rb in ovarian cancer. Adv Exp Med Biol. 2008;622:99-117. Review.

    Corney DC, Nikitin AY. MicroRNA and ovarian cancer. Histol Histopathol. 2008 Sep;23(9):1161-9.

    Duan Z, Weinstein EJ, Ji D, Ames RY, Choy E, Mankin H, Hornicek FJ. Lentiviral short hairpin RNA screen of genes associated with multidrug resistance identifies PRP-4 as a new regulator of chemoresistance in human ovarian cancer. Mol Cancer Ther. 2008. 7(8):2377-85.

    Durrant DE, Richards J, Tripathi A, Kellogg GE, Marchetti P, Eleopra M, Grisolia G, Simoni D, Lee RM. Development of water soluble derivatives of cis-3, 4′, 5-trimethoxy-3′-aminostilbene for optimization and use in cancer therapy. Invest New Drugs. 2009 27(1):41-52

    Durrant D, Richards JE, Walker WT, Baker KA, Simoni D, Lee RM. Mechanism of cell death induced by cis-3, 4′, 5-trimethoxy-3′-aminostilbene in ovarian cancer. Gynecol Oncol. 2008 110(1):110-7

    Faça VM, Ventura AP, Fitzgibbon MP, Pereira-Faça SR, Pitteri SJ, Green AE, Ireton RC, Zhang Q, Wang H, O’Briant KC, Drescher CW, Schummer M, McIntosh MW, Knudsen BS, Hanash SM. Proteomic analysis of ovarian cancer cells reveals dynamic processes of protein secretion and shedding of extra-cellular domains. PLoS One. 2008 Jun 18;3(6):e2425.

    Feng Q, Deftereos G, Hawes SE, Stern JE, Willner JB, Swisher EM, Xi L, Drescher C, Urban N, Kiviat N. DNA hypermethylation, Her-2/neu overexpression and p53 mutations in ovarian carcinoma. Gynecol Oncol. 2008 Nov;111(2):320-9

    Fishel ML, He Y, Reed AM, Chin-Sinex H, Hutchins GD, Mendonca MS, Kelley MR. Knockdown of the DNA repair and redox signaling protein Ape1/Ref-1 blocks ovarian cancer cell and tumor growth. DNA Repair (Amst). 2008. 7(2):177-86.

    Hannibal CG, Rossing MA, Wicklund KG, Cushing-Haugen KL. Analgesic drug use and risk of epithelial ovarian cancer. Am J Epidemiol. 2008 Jun 15;167(12):1430-7.

    Hellstrom I, Friedman E, Verch T, Yang Y, Korach J, Jaffar J, Swisher E, Zhang B, Ben-Baruch G, Tan MC, Goedegebuure P, Hellstrom KE. Anti-mesothelin antibodies and circulating mesothelin relate to the clinical state in ovarian cancer patients. Cancer Epidemiol Biomarkers Prev. 2008 Jun;17(6):1520-6.

    Hellstrom I, Hellstrom KE. SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and/or each other. Adv Exp Med Biol. 2008;622:15-21.

    Kelley MR, Fishel ML. DNA repair proteins as molecular targets for cancer therapeutics. Anticancer Agents Med Chem. 2008. 8(4):417-25. Review.

    Kryczek I, Wei S, Gong W, Shu X, Szeliga W, Vatan L, Chen L, Wang G, Zou W. Cutting edge: IFN-gamma enables APC to promote memory Th17 and abate Th1 cell development. J Immunol. 2008. 181(9):5842-6.

    Lafky JM, Wilken JA, Baron AT, Maihle NJ. Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. Biochim Biophys Acta. 2008. 1785(2):232-65. Review.

    Levanon K, Crum C, Drapkin R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol. 2008 Nov 10;26(32):5284-93.

    Lowe KA, Shah C, Wallace E, Anderson G, Paley P, McIntosh M, Andersen MR, Scholler N, Bergan L, Thorpe J, Urban N, Drescher CW. Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2008. 17(9):2480-7.

    Lu C, Thaker PH, Lin YG, Spannuth W, Landen CN, Merritt WM, Jennings NB, Langley RR, Gershenson DM, Yancopoulos GD, Ellis LM, Jaffe RB, Coleman RL, Sood AK. Impact of vessel maturation on antiangiogenic therapy in ovarian cancer. Am J Obstet Gynecol. 2008 Apr;198(4):477.e1-9; discussion 477.e9-10

    Martin LP, Hamilton TC, Schilder RJ. Platinum resistance: the role of DNA repair pathways. Clin Cancer Res. 2008 Mar 1;14(5):1291-5

    Matei D, Emerson RE, Schilder J, Menning N, Baldridge LA, Johnson CS, Breen T, McClean J, Stephens D, Whalen C, Sutton G. Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis : a Hoosier Oncology Group trial. Cancer. 2008. 113(4):723-32.

    McIntosh M, Anderson G, Drescher C, Hanash S, Urban N, Brown P, Gambhir SS, Coukos G, Laird PW, Nelson B, Palmer C. Ovarian cancer early detection claims are biased. Clin Cancer Res. 2008 15;14(22):7574; author reply 7577-9.

    Milne K, Barnes RO, Girardin A, Mawer MA, Nesslinger NJ, Ng A, Nielsen JS, Sahota R, Tran E, Webb JR, Wong MQ, Wick DA, Wray A, McMurtrie E, Köbel M, Kalloger SE, Gilks CB, Watson PH, Nelson BH. Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer. PLoS One. 2008;3(10):e3409

    Nelson BH. The impact of T-cell immunity on ovarian cancer outcomes. Immunol Rev. 2008 Apr;222:101-16.

    O’Donnell JD, Johnson NC, Turbeville TD, Alfonso MY, Kruk PA. BRCA1 185delAG truncation protein, BRAt, amplifies caspase-mediated apoptosis in ovarian cells. In Vitro Cell Dev Biol Anim. 2008 Sep-Oct;44(8-9):357-67.

    Palmer C, Duan X, Hawley S, Scholler N, Thorpe JD, Sahota RA, Wong MQ, Wray A, Bergan LA, Drescher CW, McIntosh MW, Brown PO, Nelson BH, Urban N. Systematic evaluation of candidate blood markers for detecting ovarian cancer. PLoS One. 2008 Jul 9;3(7):e2633.

    Palmieri RT, Wilson MA, Iversen ES, Clyde MA, Calingaert B, Moorman PG, Poole C, Anderson AR, Anderson S, Anton-Culver H, Beesley J, Hogdall E, Brewster W, Carney ME, Chen X, Chenevix-Trench G, Chang-Claude J, Cunningham JM, Dicioccio RA, Doherty JA, Easton DF, Edlund CK, Gayther SA, Gentry-Maharaj A, Goode EL, Goodman MT, Kjaer SK, Hogdall CK, Hopkins MP, Jenison EL, Blaakaer J, Lurie G, McGuire V, Menon U, Moysich KB, Ness RB, Pearce CL, Pharoah PD, Pike MC, Ramus SJ, Rossing MA, Song H, Terada KY, Vandenberg D, Vierkant RA, Wang-Gohrke S, Webb PM, Whittemore AS, Wu AH, Ziogas A, Berchuck A, Schildkraut JM; Ovarian Cancer Association Consortium; Australian Cancer Study (Ovarian Cancer Group); Australian Ovarian Cancer Study Group. Polymorphism in the IL18 gene and epithelial ovarian cancer in non-Hispanic white women. Cancer Epidemiol Biomarkers Prev. 2008 ;17(12):3567-72.

    Parsons JT, Slack-Davis J, Tilghman R, Roberts WG. Focal adhesion kinase: targeting adhesion signaling pathways for therapeutic intervention. Clin Cancer Res. 2008 Feb 1;14(3):627-32.

    Pinke DE, Kalloger SE, Francetic T, Huntsman DG, Lee JM. The prognostic significance of elongation factor eEF1A2 in ovarian cancer. Gynecol Oncol. 2008. 108(3):561-8.

    Press JZ, De Luca A, Boyd N, Young S, Troussard A, Ridge Y, Kaurah P, Kalloger SE, Blood KA, Smith M, Spellman PT, Wang Y, Miller DM, Horsman D, Faham M, Gilks CB, Gray J, Huntsman DG. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer. 2008. 8:17.

    Press JZ, Kenyon JA, Xue H, Miller MA, De Luca A, Miller DM, Huntsman DG, Gilks CB, McAlpine JN, Wang YZ. Xenografts of primary human gynecological tumors grown under the renal capsule of NOD/SCID mice show genetic stability during serial transplantation and respond to cytotoxic chemotherapy. Gynecol Oncol. 2008. 110(2):256-64.

    Rabik CA, Fishel ML, Holleran JL, Kasza K, Kelley MR, Egorin MJ, Dolan ME. Enhancement of cisplatin [cis-diammine dichloroplatinum (II)] cytotoxicity by O6-benzylguanine involves endoplasmic reticulum stress. J Pharmacol Exp Ther. 2008. 327(2):442-52.

    Rossing MA, Cushing-Haugen KL, Doherty JA, Wicklund KG. Characteristics related to the maternal intrauterine environment and risk of epithelial ovarian cancer. Ann Epidemiol. 2008 May;18(5):411-5.

    Rossing MA, Cushing-Haugen KL, Wicklund KG, Doherty JA, Weiss NS. Risk of epithelial ovarian cancer in relation to benign ovarian conditions and ovarian surgery. Cancer Causes Control. 2008 Dec;19(10):1357-64.

    Rossing MA, Cushing-Haugen KL, Wicklund KG, Weiss NS. Cigarette smoking and risk of epithelial ovarian cancer. Cancer Causes Control. 2008 May;19(4):413-20.

    Sakamoto H, Friel AM, Wood AW, Guo L, Ilic A, Seiden MV, Chung DC, Lynch MP, Serikawa T, Munro E, Oliva E, Orsulic S, Kirley SD, Foster R, Zukerberg LR, Rueda BR. Mechanisms of Cables 1 gene inactivation in human ovarian cancer development. Cancer Biol Ther. 2008 Feb;7(2):180-88.

    Scholler N, Gross JA, Garvik B, Wells L, Liu Y, Loch CM, Ramirez AB, McIntosh MW, Lampe PD, Urban N. Use of cancer-specific yeast-secreted in vivo biotinylated recombinant antibodies for serum biomarker discovery. J Transl Med. 2008 Jul 24;6:41.

    Song YJ, Kristal AR, Wicklund KG, Cushing-Haugen KL, Rossing MA. Coffee, tea, colas, and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2008 Mar;17(3):712-6.

    Smith ER, Xu XX. Ovarian ageing, follicle depletion, and cancer: a hypothesis for the aetiology of epithelial ovarian cancer involving follicle depletion. Lancet Oncol. 2008. 9(11):1108-11.

    Urban N, Drescher C. Potential and limitations in early diagnosis of ovarian cancer. Adv Exp Med Biol. 2008;622:3-14.

    Weichert W, Denkert C, Noske A, Darb-Esfahani S, Dietel M, Kalloger SE, Huntsman DG, Köbel M. Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas. Neoplasia. 2008. 10(9):1021-7.

    Yang H, Kong W, He L, Zhao JJ, O’Donnell JD, Wang J, Wenham RM, Coppola D, Kruk PA, Nicosia SV, Cheng JQ. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 2008 Jan 15;68(2):425-33. Erratum in: Cancer Res. 2008 Mar 1;68(5):1609.

    Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, Yan PS, Huang TH, Nephew KP. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 2008. 68(11):4311-20.

  • 2007

    Andersen MR, Drescher CW, Zheng Y, Bowen DJ, Wilson S, Young A, McIntosh M, Mahony BS, Lowe KA, Urban N. Changes in cancer worry associated with participation in ovarian cancer screening. Psychooncology. 2007. 16(9):814-20.

    Bergan L, Gross JA, Nevin B, Urban N, Scholler N. Development and in vitro validation of anti-mesothelin biobodies that prevent CA125/Mesothelin-dependent cell attachment. Cancer Lett. 2007 Oct 8;255(2):263-74

    DelloRusso C, Welcsh PL, Wang W, Garcia RL, King MC, Swisher EM. Functional characterization of a novel BRCA1-null ovarian cancer cell line in response to ionizing radiation. Mol Cancer Res. 2007. 5(1):35-45.

    Duan Z, Bradner J, Greenberg E, Mazitschek R, Foster R, Mahoney J, Seiden MV. 8-benzyl-4-oxo-8-azabicyclo[3.2.1]oct-2-ene-6,7-dicarboxylic acid (SD-1008), a novel janus kinase 2 inhibitor, increases chemotherapy sensitivity in human ovarian cancer cells. Mol Pharmacol. 2007. 72(5):1137-45.

    Fishel ML, He Y, Smith ML, Kelley MR. Manipulation of base excision repair to sensitize ovarian cancer cells to alkylating agent temozolomide. Clin Cancer Res. 2007. 13(1):260-7.

    Goff BA, Mandel LS, Drescher CW, Urban N, Gough S, Schurman KM, Patras J, Mahony BS, Andersen MR. Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer. 2007. 109(2):221-7.

    Guan Y, Kuo WL, Stilwell JL, Takano H, Lapuk AV, Fridlyand J, Mao JH, Yu M, Miller MA, Santos JL, Kalloger SE, Carlson JW, Ginzinger DG, Celniker SE, Mills GB, Huntsman DG, Gray JW. Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer. Clin Cancer Res. 2007. 13(19):5745-55.

    Hempel N, How T, Dong M, Murphy SK, Fields TA, Blobe GC. Loss of betaglycan expression in ovarian cancer: role in motility and invasion. Cancer Res. 2007 Jun 1;67(11):5231-8.

    Holt SK, Rossing MA, Malone KE, Schwartz SM, Weiss NS, Chen C. Ovarian cancer risk and polymorphisms involved in estrogen catabolism. Cancer Epidemiol Biomarkers and Prev. 2007. 16:481-9.

    Hu L, Ferrara N, Jaffe RB. Paracrine VEGF/VE-cadherin action on ovarian cancer permeability. Exp Biol Med (Maywood). 2006 Nov;231(10):1646-52.

    Kamat AA, Kim TJ, Landen CN Jr, Lu C, Han LY, Lin YG, Merritt WM, Thaker PH, Gershenson DM, Bischoff FZ, Heymach JV, Jaffe RB, Coleman RL, Sood AK. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res. 2007 Jan 1;67(1):281-8.

    Loch CM, Ramirez AB, Liu Y, Sather CL, Delrow JJ, Scholler N, Garvik BM, Urban ND, McIntosh MW, Lampe PD. Use of high density antibody arrays to validate and discover cancer serum biomarkers. Mol Oncol. 2007 Dec;1(3):313-20.

    Lu C, Bonome T, Li Y, Kamat AA, Han LY, Schmandt R, Coleman RL, Gershenson DM, Jaffe RB, Birrer MJ, Sood AK. Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma. Cancer Res. 2007 Feb 15;67(4):1757-68

    Lu C, Kamat AA, Lin YG, Merritt WM, Landen CN, Kim TJ, Spannuth W, Arumugam T, Han LY, Jennings NB, Logsdon C, Jaffe RB, Coleman RL, Sood AK. Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma. Clin Cancer Res. 2007 Jul 15;13(14):4209-17

    Lutz AM, Ray P, Willmann JK, Drescher C, Gambhir SS. 2-deoxy-2-[F-18]fluoro-D-glucose accumulation in ovarian carcinoma cell lines. Mol Imaging Biol. 2007 Sep-Oct;9(5):260-6.

    Martin L, Schilder R. Novel approaches in advancing the treatment of epithelial ovarian cancer: the role of angiogenesis inhibition. J Clin Oncol. 2007 Jul 10;25(20):2894-901.

    Matei D. Novel agents in ovarian cancer. Expert Opin Investig Drugs. 2007. 16(8):1227-39. Review

    Matei D, Kelich S, Cao L, Menning N, Emerson RE, Rao J, Jeng MH, Sledge GW. PDGF BB induces VEGF secretion in ovarian cancer. Cancer Biol Ther. 2007. 6(12):1951-9.

    Matei D, Satpathy M, Cao L, Lai YC, Nakshatri H, Donner DB. The platelet-derived growth factor receptor alpha is destabilized by geldanamycins in cancer cells. J Biol Chem. 2007. 282(1):445-53. Epub 2006 Nov 1.

    McIntosh MW, Liu Y, Drescher C, Urban N, Diamandis EP. Validation and characterization of human kallikrein 11 as a serum marker for diagnosis of ovarian carcinoma. Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4422-8.

    Prentice LM, Klausen C, Kalloger S, Köbel M, McKinney S, Santos JL, Kenney C, Mehl E, Gilks CB, Leung P, Swenerton K, Huntsman DG, Aparicio SA. Kisspeptin and GPR54 immunoreactivity in a cohort of 518 patients defines favourable prognosis and clear cell subtype in ovarian carcinoma. BMC Med. 2007. 5:33.

    Rossing MA, Cushing-Haugen KL, Wicklund KG, Doherty JA, Weiss NS. Menopausal hormone therapy and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2548-56.

    Satpathy M, Cao L, Pincheira R, Emerson R, Bigsby R, Nakshatri H, Matei D. Enhanced peritoneal ovarian tumor dissemination by tissue transglutaminase. Cancer Res. 2007. 67(15):7194-202.

    Scholler N, Garvik B, Hayden-Ledbetter M, Kline T, Urban N. Development of a CA125-mesothelin cell adhesion assay as a screening tool for biologics discovery. Cancer Lett. 2007 Mar 8;247(1):130-6.

    Schildkraut JM, Murphy SK, Palmieri RT, Iversen E, Moorman PG, Huang Z, Halabi S, Calingaert B, Gusberg A, Marks JR, Berchuck A. Trinucleotide repeat polymorphisms in the androgen receptor gene and risk of ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):473-80.

    Thorpe JD, Duan X, Forrest R, Lowe K, Brown L, Segal E, Nelson B, Anderson GL, McIntosh M, Urban N. Effects of blood collection conditions on ovarian cancer serum markers. PLoS One. 2007 Dec 5;2(12):e1281.

    Yang T, Wall EM, Milne K, Theiss P, Watson P, Nelson BH.

    CD8+ T cells induce complete regression of advanced ovarian cancers by an interleukin (IL)-2/IL-15 dependent mechanism. Clin Cancer Res. 2007 Dec 1;13(23):7172-80.

    Yang WL, Cai KQ, Smedberg JL, Smith ER, Klein-Szanto A, Hamilton TC, Xu XX. A reduction of cyclooxygenase 2 gene dosage counters the ovarian morphological aging and tumor phenotype in Wv mice. Am J Pathol. 2007. 170(4):1325-36.

    Yokoyama Y, Sedgewick G, Ramakrishnan S. Endostatin binding to ovarian cancer cells inhibits peritoneal attachment and dissemination. Cancer Res. 2007 Nov 15;67(22):10813-22.

    Yokoyama Y, Ramakrishnan S. Binding of endostatin to human ovarian cancer cells inhibits cell attachment. Int J Cancer. 2007 Dec 1;121(11):2402-9.

  • 2006

    Abbott KL, Nairn AV, Hall EM, Horton MB, McDonald JF, Moremen KW, Dinulescu DM, Pierce M. Focused glycomic analysis of the N-linked glycan biosynthetic pathway in ovarian cancer. Proteomics. 2008 Aug;8(16):3210-20.

    Brown LA, Irving J, Parker R, Kim H, Press JZ, Longacre TA, Chia S, Magliocco A, Makretsov N, Gilks B, Pollack J, Huntsman D. Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas. Gynecol Oncol. 2006. 100(2):264-70.

    Chi JT, Wang Z, Nuyten DS, Rodriguez EH, Schaner ME, Salim A, Wang Y, Kristensen GB, Helland A, Børresen-Dale AL, Giaccia A, Longaker MT, Hastie T, Yang GP, van de Vijver MJ, Brown PO. Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med. 2006 Mar;3(3):e47.

    Duan Z, Foster R, Bell DA, Mahoney J, Wolak K, Vaidya A, Hampel C, Lee H, Seiden MV. Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer. Clin Cancer Res. 2006. 12(17):5055-63.

    Erkanli A, Taylor DD, Dean D, Eksir F, Egger D, Geyer J, Nelson BH, Stone B, Fritsche HA, Roden RB. Application of Bayesian modeling of autologous antibody responses against ovarian tumor-associated antigens to cancer detection. Cancer Res. 2006 Feb 1;66(3):1792-8.

    Goodell V, Salazar LG, Urban N, Drescher CW, Gray H, Swensen RE, McIntosh MW, Disis ML. Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer. J Clin Oncol. 2006 Feb 10;24(5):762-8

    Gordon MS, Matei D, Aghajanian C, Matulonis UA, Brewer M, Fleming GF, Hainsworth JD, Garcia AA, Pegram MD, Schilder RJ, Cohn DE, Roman L, Derynck MK, Ng K, Lyons B, Allison DE, Eberhard DA, Pham TQ, Dere RC, Karlan BY. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol. 2006. 24(26):4324-32. Erratum in: J Clin Oncol. 2008. 26(16):2793.

    Huang Z, Wen Y, Shandilya R, Marks JR, Berchuck A, Murphy SK. High throughput detection of M6P/IGF2R intronic hypermethylation and LOH in ovarian cancer. Nucleic Acids Res. 2006. 34(2):555-63.

    Oman M, Liu J, Chen J, Durrant D, Yang HS, He Y, Kopeckova P, Kopecek J, Lee RM. Using N-(2-hydroxypropyl) methacrylamide copolymer drug bioconjugate as a novel approach to deliver a Bcl-2-targeting compound HA 14-1 in vivo. Gene Ther Mol Bio. 2006. 10:113-22.

    Pieretti-Vanmarcke R, Donahoe PK, Pearsall LA, Dinulescu DM, Connolly DC, Halpern EF, Seiden MV, MacLaughlin DT. Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer. Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17426-31.

    Scholler N, Crawford M, Sato A, Drescher CW, O’Briant KC, Kiviat N, Anderson GL, Urban N. Bead-based ELISA for validation of ovarian cancer early detection markers. Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2117-24.

    Stewart JJ, White JT, Yan X, Collins S, Drescher CW, Urban ND, Hood L, Lin B. Proteins associated with Cisplatin resistance in ovarian cancer cells identified by quantitative proteomic technology and integrated with mRNA expression levels. Mol Cell Proteomics. 2006 Mar;5(3):433-43

    Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescu DM, Connolly D, Foster R, Dombkowski D, Preffer F, Maclaughlin DT, Donahoe PK. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11154-9.

    Yee C. Adoptive T-cell therapy of cancer. Hematol Oncol Clin North Am. 2006. 20(3):711-33. Review.

  • 2005

    Andersen MR, Schroeder T, Gaul M, Moinpour C, Urban N. Using a population-based cancer registry for recruitment of newly diagnosed patients with ovarian cancer. Am J Clin Oncol. 2005. 28(1):17-20.

    Baron AT, Boardman CH, Lafky JM, Rademaker A, Liu D, Fishman DA, Podratz KC, Maihle NJ. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2005. 14(2):306-18. Erratum in: Cancer Epidemiol Biomarkers Prev. 2005. 14(6):1583.

    Benetkiewicz M, Wang Y, Schaner M, Wang P, Mantripragada KK, Buckley PG, Kristensen G, Børresen-Dale AL, Dumanski JP. High-resolution gene copy number and expression profiling of human chromosome 22 in ovarian carcinomas. Genes Chromosomes Cancer. 2005 Mar;42(3):228-37.

    Jazaeri AA, Awtrey CS, Chandramouli GV, Chuang YE, Khan J, Sotiriou C, Aprelikova O, Yee CJ, Zorn KK, Birrer MJ, Barrett JC, Boyd J. Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers. Clin Cancer Res. 2005 Sep 1;11(17):6300-10.

    Lee CH, Huntsman DG, Cheang MC, Parker RL, Brown L, Hoskins P, Miller D, Gilks CB. Assessment of Her-1, Her-2, And Her-3 expression and Her-2 amplification in advanced stage ovarian carcinoma. Int J Gynecol Pathol. 2005. 24(2):147-52.

    Lee CH, Xue H, Sutcliffe M, Gout PW, Huntsman DG, Miller DM, Gilks CB, Wang YZ. Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential models. Gynecol Oncol. 2005. 96(1):48-55.

    Schaner ME, Davidson B, Skrede M, Reich R, Flørenes VA, Risberg B, Berner A, Goldberg I, Givant-Horwitz V, Tropè CG, Kristensen GB, Nesland JM, Børresen-Dale AL. Variation in gene expression patterns in effusions and primary tumors from serous ovarian cancer patients. Mol Cancer. 2005. 4:26.

    Yokoyama Y, Ramakrishnan S. Addition of an aminopeptidase N-binding sequence to human endostatin improves inhibition of ovarian carcinoma growth. Cancer. 2005 Jul 15;104(2):321-31.

  • 2004

    Andersen MR, Nelson J, Peacock S, Giedzinska A, Dresher C, Bowen D, Urban N. Worry about ovarian cancer risk and use of screening by high-risk women: how you recruit affects what you find. Am J Med Genet A. 2004. 129A(2):130-5.

    Andersen MR, Urban N, Ramsey S, Briss PA. Examining the cost-effectiveness of cancer screening promotion. Cancer. 2004. 101(5 Suppl):1229-38. Review.

    Drescher CW, Nelson J, Peacock S, Andersen MR, McIntosh MW, Urban N. Compliance of average- and intermediate-risk women to semiannual ovarian cancer screening. Cancer Epidemiol Biomarkers Prev. 2004. 13(4):600-6.

    McIntosh MW, Drescher C, Karlan B, Scholler N, Urban N, Hellstrom KE, Hellstrom I. Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. Gynecol Oncol. 2004 Oct;95(1):9-15.

  • 2003

    Andersen MR, Bowen D, Yasui Y, McTiernan A. Awareness and concern about ovarian cancer among women at risk because of a family history of breast or ovarian cancer. Am J Obstet Gynecol. 2003. 189(4 Suppl):S42-7.

    Baron AT, Cora EM, Lafky JM, Boardman CH, Buenafe MC, Rademaker A, Liu D, Fishman DA, Podratz KC, Maihle NJ. Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2003. 12(2):103-13.

    Schaner ME, Ross DT, Ciaravino G, Sorlie T, Troyanskaya O, Diehn M, Wang YC, Duran GE, Sikic TL, Caldeira S, Skomedal H, Tu IP, Hernandez-Boussard T, Johnson SW, O’Dwyer PJ, Fero MJ, Kristensen GB, Borresen-Dale AL, Hastie T, Tibshirani R, van de Rijn M, Teng NN, Longacre TA, Botstein D, Brown PO, Sikic BI. Gene expression patterns in ovarian carcinomas. Mol Biol Cell. 2003. 14(11):4376-86.

    Stone B, Schummer M, Paley PJ, Thompson L, Stewart J, Ford M, Crawford M, Urban N, O’Briant K, Nelson BH. Serologic analysis of ovarian tumor antigens reveals a bias toward antigens encoded on 17q. Int J Cancer. 2003 Mar 10;104(1):73-84.

Challenge Grant Award

Scientist in lab

Pilot Study Deadline Submission

This grant competition is open September 1 – December 1, 2016. To be eligible, initial applications must be received by December 1, 2016 (5pm PT).

Apply Now

Grant award recipient authored publications published by top scientific journals: 55%